<SEC-DOCUMENT>0001193125-25-211357.txt : 20250922
<SEC-HEADER>0001193125-25-211357.hdr.sgml : 20250922
<ACCEPTANCE-DATETIME>20250922162058
ACCESSION NUMBER:		0001193125-25-211357
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250922
DATE AS OF CHANGE:		20250922

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LENZ Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001815776
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				844867570
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-92660
		FILM NUMBER:		251330271

	BUSINESS ADDRESS:	
		STREET 1:		201 LOMAS SANTA FE DRIVE, SUITE 300
		CITY:			SOLANA BEACH
		STATE:			CA
		ZIP:			92075
		BUSINESS PHONE:		858-925-7000

	MAIL ADDRESS:	
		STREET 1:		201 LOMAS SANTA FE DRIVE, SUITE 300
		CITY:			SOLANA BEACH
		STATE:			CA
		ZIP:			92075

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Graphite Bio, Inc.
		DATE OF NAME CHANGE:	20210312

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Integral Medicines, Inc.
		DATE OF NAME CHANGE:	20200622

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Versant Venture Capital VI, L.P.
		CENTRAL INDEX KEY:			0001687880
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		ONE SANSOME STREET, SUITE 1650
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94104
		BUSINESS PHONE:		(415) 801-8100

	MAIL ADDRESS:	
		STREET 1:		ONE SANSOME STREET, SUITE 1650
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94104
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001687880</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>8</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.00001 per share</securitiesClassTitle>
      <dateOfEvent>09/18/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001815776</issuerCIK>
        <issuerCUSIP>52635N103</issuerCUSIP>
        <issuerName>LENZ Therapeutics, Inc.</issuerName>
        <address>
          <street1 xmlns="http://www.sec.gov/edgar/common">201 Lomas Santa Fe Dr.</street1>
          <street2 xmlns="http://www.sec.gov/edgar/common">Suite 300</street2>
          <city xmlns="http://www.sec.gov/edgar/common">Solana Beach</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">CA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">92075</zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Max Eisenberg</personName>
          <personPhoneNum>415-801-8100</personPhoneNum>
          <personAddress>
            <street1 xmlns="http://www.sec.gov/edgar/common">One Sansome Street, Suite 1650</street1>
            <city xmlns="http://www.sec.gov/edgar/common">San Francisco</city>
            <stateOrCountry xmlns="http://www.sec.gov/edgar/common">CA</stateOrCountry>
            <zipCode xmlns="http://www.sec.gov/edgar/common">94104</zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001687880</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Versant Venture Capital VI, L.P.</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>1183543</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>1183543</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
        <aggregateAmountOwned>1183543</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.1</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>All shares are held by Versant VI (as defined in Item 2(a) of the Original Schedule 13D (as defined in Item 1 below)). Versant Ventures VI GP-GP (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of Versant Ventures VI GP (as defined in Item 2(a) of the Original Schedule 13D), which is the general partner of Versant VI. Each of Versant Ventures VI GP-GP and Versant Ventures VI GP may be deemed to share voting, investment and dispositive power with respect to the shares held by Versant VI.

The percentage in Row 13 is based on 28,522,096 shares of Common Stock (as defined in Item 1 of the Original Schedule 13D) outstanding as of July 24, 2025, as set forth in the Issuer's quarterly report on Form 10-Q for the quarter ended June 30, 2025, filed with the United States Securities and Exchange Commission (the "Commission") on July 30, 2025 (the "Form 10-Q").</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001777654</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Versant Ventures VI GP, L.P.</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>1183543</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>1183543</sharedDispositivePower>
        <aggregateAmountOwned>1183543</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.1</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>All shares are held by Versant VI. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP, which is the general partner of Versant VI. Each of Versant Ventures VI GP-GP and Versant Ventures VI GP may be deemed to share voting, investment and dispositive power with respect to the shares held by Versant VI.

The percentage in Row 13 is based on 28,522,096 shares of Common Stock outstanding as of July 24, 2025, as reported by the Issuer in the Form 10-Q.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001777652</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Versant Ventures VI GP-GP, LLC</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>1183543</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>1183543</sharedDispositivePower>
        <aggregateAmountOwned>1183543</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.1</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>
All shares are held by Versant VI. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP, which is the general partner of Versant VI. Each of Versant Ventures VI GP-GP and Versant Ventures VI GP may be deemed to share voting, investment and dispositive power with respect to the shares held by Versant VI.

The percentage in Row 13 is based on 28,522,096 shares of Common Stock outstanding as of July 24, 2025, as reported by the Issuer in the Form 10-Q.
</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001832235</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Versant Vantage II, L.P.</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>842162</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>842162</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
        <aggregateAmountOwned>842162</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>3.0</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>
All shares are held by Versant Vantage II (as defined in Item 2(a) of the Original Schedule 13D). Versant Vantage II GP (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of Versant Vantage II, and Versant Vantage II GP-GP (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of Versant Vantage II GP. Each of Versant Vantage II GP and Versant Vantage II GP-GP share voting, investment and dispositive power over the shares held by Versant Vantage II.

The percentage in Row 13 is based on 28,522,096 shares of Common Stock outstanding as of July 24, 2025, as reported by the Issuer in the Form 10-Q.
</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001839790</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Versant Vantage II GP, L.P.</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>842162</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>842162</sharedDispositivePower>
        <aggregateAmountOwned>842162</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>3.0</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>
All shares are held by Versant Vantage II. Versant Vantage II GP is the general partner of Versant Vantage II, and Versant Vantage II GP-GP is the general partner of Versant Vantage II GP. Each of Versant Vantage II GP and Versant Vantage II GP-GP share voting, investment and dispositive power over the shares held by Versant Vantage II.

The percentage in Row 13 is based on 28,522,096 shares of Common Stock outstanding as of July 24, 2025, as reported by the Issuer in the Form 10-Q.
</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001839789</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Versant Vantage II GP-GP, LLC</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>842162</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>842162</sharedDispositivePower>
        <aggregateAmountOwned>842162</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>3.0</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>
All shares are held by Versant Vantage II. Versant Vantage II GP is the general partner of Versant Vantage II, and Versant Vantage II GP-GP is the general partner of Versant Vantage II GP. Each of Versant Vantage II GP and Versant Vantage II GP-GP share voting, investment and dispositive power over the shares held by Versant Vantage II.

The percentage in Row 13 is based on 28,522,096 shares of Common Stock outstanding as of July 24, 2025, as reported by the Issuer in the Form 10-Q.
</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001750266</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Versant Venture Capital VII, L.P.</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>926691</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>926691</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
        <aggregateAmountOwned>926691</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>3.2</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>
Consists of (i) 856,157 shares of Common Stock held by Versant VII (as defined in Item 2(a) of the Original Schedule 13D) and (ii) 70,534 shares of Common Stock issuable upon exercise of a warrant to purchase shares of Common Stock (the "Warrant") held by Versant VII. Versant Ventures VII GP-GP (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of Versant Ventures VII GP (as defined in Item 2(a) of the Original Schedule 13D), which is the general partner of Versant VII. Each of Versant Ventures VII GP-GP and Versant Ventures VII GP may be deemed to share voting, investment and dispositive power with respect to the shares held by Versant VII.

The percentage in Row 13 is based upon 28,592,630 shares of Common Stock, which consists of (i) 28,522,096 shares of Common Stock outstanding as of July 24, 2025, as set forth in the Form 10-Q, plus (ii) 70,534 shares of Common Stock issuable upon exercise of the Warrant held by Versant VII.

</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001777655</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Versant Ventures VII GP, L.P.</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>926691</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>926691</sharedDispositivePower>
        <aggregateAmountOwned>926691</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>3.2</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>
Consists of (i) 856,157 shares of Common Stock held by Versant VII and (ii) 70,534 shares of Common Stock issuable upon exercise of the Warrant held by Versant VII. Versant Ventures VII GP-GP is the general partner of Versant Ventures VII GP, which is the general partner of Versant VII. Each of Versant Ventures VII GP-GP and Versant Ventures VII GP may be deemed to share voting, investment and dispositive power with respect to the shares held by Versant VII.

The percentage in Row 13 is based upon 28,592,630 shares of Common Stock, which consists of (i) 28,522,096 shares of Common Stock outstanding as of July 24, 2025, as set forth in the Form 10-Q, plus (ii) 70,534 shares of Common Stock issuable upon exercise of the Warrant held by Versant VII.

</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001777656</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Versant Ventures VII GP-GP, LLC</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>926691</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>926691</sharedDispositivePower>
        <aggregateAmountOwned>926691</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>3.2</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>
Consists of (i) 856,157 shares of Common Stock held by Versant VII and (ii) 70,534 shares of Common Stock issuable upon exercise of the Warrant held by Versant VII. Versant Ventures VII GP-GP is the general partner of Versant Ventures VII GP, which is the general partner of Versant VII. Each of Versant Ventures VII GP-GP and Versant Ventures VII GP may be deemed to share voting, investment and dispositive power with respect to the shares held by Versant VII.

The percentage in Row 13 is based upon 28,592,630 shares of Common Stock, which consists of (i) 28,522,096 shares of Common Stock outstanding as of July 24, 2025, as set forth in the Form 10-Q, plus (ii) 70,534 shares of Common Stock issuable upon exercise of the Warrant held by Versant VII.

</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, par value $0.00001 per share</securityTitle>
        <issuerName>LENZ Therapeutics, Inc.</issuerName>
        <issuerPrincipalAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">201 Lomas Santa Fe Dr.</street1>
          <street2 xmlns="http://www.sec.gov/edgar/common">Suite 300</street2>
          <city xmlns="http://www.sec.gov/edgar/common">Solana Beach</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">CA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">92075</zipCode>
        </issuerPrincipalAddress>
        <commentText>
This Amendment No. 8 (this "Amendment") amends and supplements the Schedule 13D originally filed by certain of the Reporting Persons with the Commission on July 9, 2021 as it has been amended by Amendment No. 1 that was filed with the Commission on November 17, 2023, Amendment No. 2 that was filed with the Commission on March 25, 2024, Amendment No. 3 that was filed with the Commission on November 8, 2024, Amendment No. 4 that was filed with the commission on June 12, 2025, Amendment No. 5 that was filed with the Commission on June 24, 2025, Amendment No. 6 that was filed with the Commission on July 14, 2025 and Amendment No. 7 that was filed with the commission on August 20, 2025 (collectively, the "Original Schedule 13D"). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D. </commentText>
      </item1>
      <item5>
        <percentageOfClassSecurities>See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.</percentageOfClassSecurities>
        <numberOfShares>See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.</numberOfShares>
        <transactionDesc>On August 22, 2025, Versant VI sold 26,161 shares of Common Stock at a price per share of $40.1513 for aggregate proceeds of approximately $1,050,398.16.

On August 22, 2025, Versant VII sold 12,885 shares of Common Stock at a price per share of $40.1513 for aggregate proceeds of approximately $517,349.50.

On August 25, 2025, Versant VI sold 52,419 shares of Common Stock at a price per share of $39.5417 for aggregate proceeds of approximately $2,072,736.37.

On August 25, 2025, Versant VII sold 25,818 shares of Common Stock at a price per share of $39.5417 for aggregate proceeds of approximately $1,020,887.61.

On August 26, 2025, Versant VI sold 47,443 shares of Common Stock at a price per share of $39.0129 for aggregate proceeds of approximately $1,850,889.01.

On August 26, 2025, Versant VII sold 23,368 shares of Common Stock at a price per share of $39.0129 for aggregate proceeds of approximately $911,653.45.

On September 18, 2025, Versant VI sold 90,654 shares of Common Stock at a price per share of $42.2335 for aggregate proceeds of approximately $3,828,631.71.

On September 18, 2025, Versant VII sold 44,650 shares of Common Stock at a price per share of $42.2335 for aggregate proceeds of approximately $1,885,723.80.</transactionDesc>
      </item5>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Versant Venture Capital VI, L.P.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/Max Eisenberg</signature>
          <title>Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the GP of Versant Ventures VI GP, L.P., the GP of Versant Venture Capital VI, L.P.</title>
          <date>09/22/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Versant Ventures VI GP, L.P.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/Max Eisenberg</signature>
          <title>Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the General Partner of Versant Ventures VI GP, L.P.</title>
          <date>09/22/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Versant Ventures VI GP-GP, LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/Max Eisenberg</signature>
          <title>Max Eisenberg/COO</title>
          <date>09/22/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Versant Vantage II, L.P.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/Max Eisenberg</signature>
          <title>Max Eisenberg/COO of Versant Vantage II GP-GP, LLC, the GP of Versant Vantage II GP, L.P., the GP of Versant Vantage II, L.P.</title>
          <date>09/22/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Versant Vantage II GP, L.P.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/Max Eisenberg</signature>
          <title>Max Eisenberg/COO of Versant Vantage II GP-GP, LLC, the General Partner of Versant Vantage II GP, L.P.</title>
          <date>09/22/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Versant Vantage II GP-GP, LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/Max Eisenberg</signature>
          <title>Max Eisenberg/COO</title>
          <date>09/22/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Versant Venture Capital VII, L.P.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/Max Eisenberg</signature>
          <title>Max Eisenberg/COO of Versant Ventures VII GP-GP, LLC, the GP of Versant Ventures VII GP, L.P., the GP of Versant Venture Capital VII, L.P.</title>
          <date>09/22/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Versant Ventures VII GP, L.P.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/Max Eisenberg</signature>
          <title>Max Eisenberg/COO of Versant Ventures VII GP-GP, LLC, the General Partner of Versant Ventures VII GP, L.P.</title>
          <date>09/22/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Versant Ventures VII GP-GP, LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/Max Eisenberg</signature>
          <title>Max Eisenberg/COO</title>
          <date>09/22/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
